An Ipca Labs plant savaged in an FDA warning letter three years ago continues to fail manufacturing standards that would assure its drugs are safe.

Two C-level execs, including one who's under blame for an FDA warning letter, will leave Bayer first thing next year.

Catalent has invested $9 million in a clinical supply facility and Sagent has access to expanded manufacturing in Canada.

Troubled Mallinckrodt is selling sell its CDMO unit for up to $250 million, but that is a drop in the bucket of what it may need going forward.

Takeda is having to recall the Natpara from the market, a move it says may be very challenging for patients.  

Will your blood pressure meds give you cancer? Probably not, the FDA says.

A Novartis ingredient operation in China is being hived off as the Swiss drugmaker continues its drive to cut manufacturing jobs.

The clock is ticking down for the 400 workers at a Novartis plant which was put on the block last year as the company cuts costs to finance new therapies.